Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1835 results
June 2021
-
Press Release
Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021
Phase III JUNIPERA study met its primary endpoint, with Cosentyx® (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P<.001) in pediatric… -
Press Release
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1…
May 2021
-
Press Release
Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
Beovu (brolucizumab) met MERLIN’s primary endpoint of non-inferiority in change in best corrected visual acuity from baseline and superiority on anatomical secondary endpoints at year one versus… -
Featured News
Novartis Hematology: Relentless Pursuit of a Cure
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
-
Press Release
Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalizationThe study plans to enroll 2100 patients, with 400… -
Pulse Update
Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
-
Press Release
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be… -
Press Release
Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needsKundl, Austria further strengthens… -
Press Release
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999With other innovations, the Novartis artemisinin-based… -
Press Release
US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients Sandoz is disappointed US patients affected by… -
Featured News
World Asthma Day 2021
Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.
-
Story Access to Healthcare
Fighting MS through innovation
Investing in innovative treatments is vital to alleviate the suffering caused by multiple sclerosis (MS).